Fig. 1.Rapid clinical response of hidradenitis suppurativa (HS) to secukinumab treatment.Clinical images of the genital and gluteal region (A) before and (B) after 8 weeks of treatment with the interleukin-17A antibody secukinumab, demonstrating rapid reduction in inflammatory nodules and signs of cutaneous inflammation.
No takes yet. Share an insight, caveat, or question.
Schuch et al. (2017) studied this question.